Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2022; 10(14): 4425-4435
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4425
Hematopoiesis reconstitution and anti-tumor effectiveness of Pai-Neng-Da capsule in acute leukemia patients with haploidentical hematopoietic stem cell transplantation
Jiao-Jiao Yuan, Ying Lu, Jun-Jie Cao, Ren-Zhi Pei, Rui-Lan Gao
Jiao-Jiao Yuan, Ying Lu, Jun-Jie Cao, Ren-Zhi Pei, Department of Hematology, The Affiliated People’s Hospital of Ningbo University, Ningbo 315000, Zhejiang Province, China
Rui-Lan Gao, Institute of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hang Zhou 310006, Zhejiang Province, China
Author contributions: Yuan JJ wrote the first draft of the manuscript; Lu Y critically reviewed and revised the manuscript; Cao JJ and Pei RZ collected and analyzed the clinical data; Gao RL designed the study and confirmed the statistical methods for the research; all the authors read and approved the final manuscript.
Supported by The Zhejiang Provincial Science and Technology Program of Traditional Chinese Medicine, No. 2017ZA129 and No. 2018ZA112.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Affiliated People’s Hospital of Ningbo University Institutional Review Board (Approval No.2017022).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui-Lan Gao, PhD, Professor, Institute of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Youdian Road, Hang Zhou 310006, Zhejiang Province, China. gaorl2021@163.com
Received: August 19, 2021
Peer-review started: August 19, 2021
First decision: November 11, 2021
Revised: March 25, 2022
Article in press: March 25, 2022
Published online: May 16, 2022
Processing time: 267 Days and 1.5 Hours
Core Tip

Core Tip: New Chinese patent medicine Pai-Neng-Da (PND) Capsule exerts dual effect of promoting hematopoiesis recovery and regulating immunity. However, the efficacy of PND capsule in patients with haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has not yet been reported. To the best of our knowledge, this is the first study that evaluated the effectiveness of PND capsule in acute leukemia (AL) patients following haplo-HSCT. Our study showed that PND capsule could promote hematopoietic function recovery, improve the therapeutic efficacy according to Chinese medical symptom scores, present anti-tumor effectiveness, and prolong the survival of AL patients who underwent haplo-HSCT.